Acceptability in clinical practice of MSCopilot, a smartphone application for the digital self-assessment of patients living with MS
Author(s): ,
E. Maillart
Affiliations:
Neurology, Pitie-Salpetriere Hospital, APHP, Paris
,
P. Labauge
Affiliations:
Neurology, Montpellier University Hospital, Montpellier
,
M. Cohen
Affiliations:
Neurology, Nice University Hospital, Nice
,
A. Maarouf
Affiliations:
Neurology, Pôle de Neurosciences Cliniques, APHM, Hôpital de la Timone, Marseille
,
S. Vukusic
Affiliations:
Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique
,
C. Donze
Affiliations:
Department of Physical and Rehabilitation Medicine, Groupe Hospitalier de l’Institut Catholique de Lille, Lille
,
P. Gallien
Affiliations:
Pole of rehabilitation and physical medicine, Saint-Hélier, Rennes
,
J. De Seze
Affiliations:
Neurology, Strasbourg University, Hôpital Civil, Strasbourg
,
B. Bourre
Affiliations:
Neurology, Rouen University Hospital, Rouen
,
T. Moreau
Affiliations:
Neurology, Dijon University Hospital, Dijon
,
S. Bieuvelet
Affiliations:
Ad Scientiam, Brain & Spine Institute (ICM), Pitie-Salpetriere Hospital, Paris
,
F. Bertillot
Affiliations:
Ad Scientiam, Brain & Spine Institute (ICM), Pitie-Salpetriere Hospital, Paris
,
S. Zinai
Affiliations:
Ad Scientiam, Brain & Spine Institute (ICM), Pitie-Salpetriere Hospital, Paris
A. Tourbah
Affiliations:
CHU de Reims and URCA, Reims, France
ECTRIMS Online Library. Maillart E. Oct 11, 2018; 228545; P702
Elisabeth Maillart
Elisabeth Maillart
Contributions
Abstract

Abstract: P702

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Clinical assessment tools

Introduction: Users' acceptance is essential for the implementation of new digital tools in routine medical care of patients living with multiple sclerosis (PwMS). MSCopilot (MSC) is a CE-marked software for the self-assessment of PwMS covering 4 measures: walking perimeter (WP), upper-limb dexterity, cognition and low-contrast visual acuity (LCVA). This application aims at providing clinically validated remote monitoring for PwMS and clinicians. MSC potential benefits are: i) Standardisation of tests with automatic calculation of individual and composite z-scores, ii) Comparability of results with Multiple Sclerosis Functional Composite (MSFC), iii) Accurate measurement of the walking perimeter, in PwMS' real-life, and iv) saving time during medical visits
Objective: This study assessed the potential of MSC for the digital self-assessment of MS-related disabilities in clinical practice (NCT03148938)
Methods: a total of 146 PwMS fulfilling the 2010 revised McDonald criteria and 76 healthy controls (HC) will be recruited in 11 French centres, performing successively MSC digital tests (e.g. WP, dexterity, cognition and LCVA) and standard tests [EDSS, Nine-Hole Peg Test, Symbol Digit Modalities Test (SDMT), Timed 25-Foot Walk (T25FW) and Sloan Low Contrast Letter Acuity Test (SLCLAT)]. 60 PwMS will be assessed one month later for test-retest reliability. Satisfaction is evaluated via anonymised self-reported questionnaires.
Results: 48 PwMS surveys were collected. Mean (median) duration of digital tests, 48min (40min) and standard tests, 46min (30min) were equivalent (p=0.81). The duration of digital tests was found rather short by 87% of PwMS vs 70% for the standard test (p=0.046); 87% of PwMS were favourable to the use of a mobile app as part of medical care and 78% believed that using MSC once a month would be easy to perform. Moreover, 93% felt that the data collected between consultations could improve the management of their disease, 87% preferred digital over standard evaluations and 97% would recommend MSC to other PwMS. Inclusions will end by the first of June, and final results will be presented during the meeting.
Conclusion: MSC is suitable for the self-assessment of MS disabilities in real life, with excellent acceptance by PwMS.
Disclosure: This project was sponsored by Ad Scientiam SAS and has received a grant from Roche SAS France.
E.Maillart has received consulting and lecturing fees, travel grants, from ad Scientiam, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi, and Teva Pharma, and research
support from Novartis and Roche.
P. Labauge: Honoraria and consulting fees from Biogen,Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche and Medday. Research supports from Biogen, Novartis, Sanofi-Genzyme, Roche and Medday.
M. Cohen, P Gallien, C Donze, A Maarouf, T Moreau: nothing to disclose
S. Vukusic has received consulting and lecturing fees, travel grants and research support from Biogen, Celgene, Genzyme, Medday, Merck Serono, Novartis, Roche, Sanofi Aventis and Teva Pharma.
B Bourre serves on scientific advisory board for Merck Serono and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Roche and Teva.S. Bieuvelet, F. Bertillot are employees of Ad Scientiam
S. Zinaï is employee of, and stakeholder in, Ad Scientiam
A Tourbah has received consulting and lecturing fees, travel grants and research support from Medday, Biogen, Sanofi-Genzyme, Novartis, Merck Serono, Teva Pharma, and Roche

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies